All Stories

  1. Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist

    Article • Heliyon, November 2019, Elsevier

    Dr. Shinji Hatakeyama

  2. A novel tissue-selective β2-adrenoceptor agonist with minimized cardiovascular effects, 5-HOB, attenuates neuropathic pain in mice

    Article • BMC Research Notes, July 2019, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  3. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models

    Article • BMC Research Notes, June 2019, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  4. Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis

    Article • BMC Research Notes, April 2019, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  5. Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β2-Adrenoceptor Agonist with Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular Safety Window in Preclinical Studies

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr. Shinji Hatakeyama

  6. Mouse models of cancer-induced cachexia: Hind limb muscle mass and evoked force as readouts

    Article • Biochemical and Biophysical Research Communications, September 2018, Elsevier

    Dr. Shinji Hatakeyama

  7. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival

    Article • Nature Communications, November 2017, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  8. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling

    Article • Scientific Reports, May 2017, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  9. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments

    Article • Skeletal Muscle, July 2016, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  10. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells

    Article • PLoS ONE, June 2015, PLOS

    Dr. Shinji Hatakeyama

  11. Clinical Classification of Cancer Cachexia: Phenotypic Correlates in Human Skeletal Muscle

    Article • PLoS ONE, January 2014, PLOS

    Dr. Shinji Hatakeyama

  12. An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

    Article • Molecular and Cellular Biology, December 2013, ASM Journals

    Dr. Shinji Hatakeyama

  13. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma

    Article • Oral Oncology, November 2012, Elsevier

    Dr. Shinji Hatakeyama

  14. Correction: YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

    Article • Cancer Research, July 2012, American Association for Cancer Research (AACR)

    Dr. Shinji Hatakeyama

  15. Blockade of the Activin Receptor IIB Activates Functional Brown Adipogenesis and Thermogenesis by Inducing Mitochondrial Oxidative Metabolism

    Article • Molecular and Cellular Biology, May 2012, ASM Journals

    Dr. Shinji Hatakeyama

  16. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

    Article • Anti-Cancer Drugs, June 2011, Wolters Kluwer Health

    Dr. Shinji Hatakeyama

  17. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo

    Article • Experimental Cell Research, May 2011, Elsevier

    Dr. Shinji Hatakeyama

  18. Inhibition of Podocyte FAK Protects against Proteinuria and Foot Process Effacement

    Article • Journal of the American Society of Nephrology, June 2010, American Society of Nephrology

    Dr. Shinji Hatakeyama

  19. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer

    Article • Oncology Reports, March 2010, Spandidos Publications

    Dr. Shinji Hatakeyama

  20. Alleviation of High-Fat Diet-Induced Fatty Liver Damage in Group IVA Phospholipase A2-Knockout Mice

    Article • PLoS ONE, December 2009, PLOS

    Dr. Shinji Hatakeyama

  21. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size

    Article • AJP Cell Physiology, June 2009, American Physiological Society

    Dr. Shinji Hatakeyama

  22. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor

    Article • Molecular Cancer Therapeutics, January 2009, American Association for Cancer Research (AACR)

    Dr. Shinji Hatakeyama

  23. Analyses of Group III Secreted Phospholipase A2Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis

    Article • Journal of Biological Chemistry, September 2008, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Shinji Hatakeyama

  24. Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma In vitro and In vivo

    Article • Clinical Cancer Research, July 2008, American Association for Cancer Research (AACR)

    Dr. Shinji Hatakeyama

  25. Group IVA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver

    Article • Prostaglandins & Other Lipid Mediators, June 2008, Elsevier

    Dr. Shinji Hatakeyama

  26. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts

    Article • Cancer Research, September 2007, American Association for Cancer Research (AACR)

    Dr. Shinji Hatakeyama

  27. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo

    Article • Molecular Cancer Therapeutics, April 2007, American Association for Cancer Research (AACR)

    Dr. Shinji Hatakeyama

  28. 561 POSTER Discovery of a novel FAK inhibitor, NVP-TAE226, and its activities on in vivo and in vitro models

    Article • European Journal of Cancer Supplements, November 2006, Elsevier

    Dr. Shinji Hatakeyama

  29. 579 POSTER NVP-TAE226, an inhibitor of FAK, induces regression of solid tumor

    Article • European Journal of Cancer Supplements, November 2006, Elsevier

    Dr. Shinji Hatakeyama

  30. Variant forms of upstream stimulatory factors (USFs) control the promoter activity ofhTERT, the human gene encoding the catalytic subunit of telomerase

    Article • FEBS Letters, May 2002, Wiley

    Dr. Shinji Hatakeyama

  31. Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice

    Article • Genes to Cells, October 1999, Wiley

    Dr. Shinji Hatakeyama

  32. JTB: A novel membrane protein gene at 1q21 rearranged in a jumping translocation

    Article • Oncogene, March 1999, Springer Science + Business Media

    Dr. Shinji Hatakeyama

  33. ICE: a novel and efficient method for isolation of chromosomal ends

    Article • Genetic Analysis Biomolecular Engineering, July 1997, Elsevier

    Dr. Shinji Hatakeyama

  34. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells

    Article • Oncology Reports, January 1994, Spandidos Publications

    Dr. Shinji Hatakeyama